Search results
Showing 1 to 10 of 10 results for sacituzumab govitecan
Evidence-based recommendations on sacituzumab govetican (Trodelvy) for treating unresectable, triple-negative locally advanced or metastatic breast cancer in adults after 2 or more systemic therapies, at least 1 of which was for advanced disease.
In development [GID-TA10919] Expected publication date: TBC
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy in adults.
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433
Awaiting development [GID-TA11489] Expected publication date: TBC
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]
In development [GID-TA11009] Expected publication date: TBC
In development [GID-TA11441] Expected publication date: TBC
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018.
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
NICE has issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or metastatic triple negative breast cancer.